Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology
Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK- Cells for the Treatment of Primary Immunodeficiencies, and Cancers.
November 05th, 2021
Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell™) for AML and ALL
Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 (ProTcell™) for rapid immune reconstitution, announced today that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center (MSK) has approved the commencement of the Company’s phase 1/2 clinical trial. MSK will start enrolling patients in November, 2021.
October 13, 2021
TNFα-supplemented DL-4 culture system supports first-in-clinic Smart Immune ProTcell™ technology for immuno-deficient patients fighting cancers and infections
Smart Immune’s unique ex-vivo biomimetic ProTcell™ ‘thymus in a dish’ platform technology, designed to generate specific human T-cell progenitor cells at scale with high purity, homogeneity, and yield, has been reinforced by data published in the peer-reviewed journal Cellular & Molecular Immunology.
September 29th, 2021
Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell progenitor Product SMART 101 (ProTcell™) for AML and ALL.
May 10th, 2021
A l’hôpital Necker, une start-up mise sur un traitement post-greffe innovant
Smart Immune Announces the Launch of its T Cell Progenitor-based Platform of Next-Generation Biotherapies for Severe Infections and Leukemia .
Smart Immune will be in San Francisco
During the 38th annual J.P Morgan Healthcare conference. Following our latest announcement on the the launch of the T cell progenitor-based platform, we are looking forward to meeting there and share our latest progress.